MVC-COV1901

MVC-COV1901 Uses, Dosage, Side Effects, Food Interaction and all others data.

MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as ISS-1018), for use with its vaccine. As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210).

Trade Name MVC-COV1901
Generic MVC-COV1901
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
MVC-COV1901
MVC-COV1901

Innovators Monograph

You find simplified version here MVC-COV1901


*** Taking medicines without doctor's advice can cause long-term problems.
Share